-
1 Comment
Lineage Cell Therapeutics, Inc is currently in a long term uptrend where the price is trading 27.2% above its 200 day moving average.
From a valuation standpoint, the stock is 1510.0% more expensive than other stocks from the Other sector with a price to sales ratio of 204.3.
Lineage Cell Therapeutics, Inc's total revenue sank by 71.4% to $355K since the same quarter in the previous year.
Its net income has increased by 145.3% to $2M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.4% to $-6M since the same quarter in the previous year.
Based on the above factors, Lineage Cell Therapeutics, Inc gets an overall score of 2/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | US53566P1093 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Dividend Yield | None |
| Beta | 1.33 |
| Market Cap | 77M |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BT3.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
